NCT07562360

Brief Summary

this study will be conducted to investigate the effect of TECAR Therapy on quality of landing, healing and Function in patient with Calf Muscle Strain.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
7mo left

Started May 2026

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
May 2026Dec 2026

First Submitted

Initial submission to the registry

April 25, 2026

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 1, 2026

Completed
Same day until next milestone

Study Start

First participant enrolled

May 1, 2026

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2026

Last Updated

May 1, 2026

Status Verified

April 1, 2026

Enrollment Period

7 months

First QC Date

April 25, 2026

Last Update Submit

April 25, 2026

Conditions

Muscle Strain

Keywords

Tecar TherapyCalf Muscle Strain Injuries

Outcome Measures

Primary Outcomes (1)

  • size of injury

    ultrasonography device will be used to assess size of injury

    up to 12 weeks

Secondary Outcomes (2)

  • landing error score system

    up to 12 weeks

  • jump height

    up to 12 weeks

Study Arms (2)

TECAR therapy

EXPERIMENTAL

Thirty patients will receive TECAR therapy combined with conventional treatment three times per week for 12 weeks.

Other: TECAR therapyOther: conventional treatment

conventional treatment

ACTIVE COMPARATOR

Thirty patients will receive conventional treatment three times per week for 12 weeks.

Other: conventional treatment

Interventions

TECAR therapyOTHER

The TECAR intervention was administered to the calf muscle using the Zimmer devicein capacitive (CAP) mode for a duration of 20 min. The therapy was applied with the signal at a variable power with a maximum of 300 W. The frequency used was 500 kHz with an intensity of 40%. The intervention was standardized to a distal-to-proximal stroking rhythm with moderate pressure. For the TECAR intervention, the capacitive (CAP) mode at 500 kHz with 40% intensity and a maximum power of 300 W was chosen to optimize deep tissue heating and promote local blood flow and tissue recovery. The 20 min duration reflects protocols commonly used in therapeutic settings for muscle recovery and rehabilitation plus conventional therapy

TECAR therapy
conventional treatmentOTHER

the patients will receive stretching exercises of the gastrocnemius (straight leg) and soleus (bended knee), eccentric exercises for calf muscles, plus plyometric exercises.

TECAR therapyconventional treatment

Eligibility Criteria

Age16 Years - 39 Years
Sexmale(Gender-based eligibility)
Gender Eligibility DetailsThe patients will be athletic males with calf muscle injuries.
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • Aged between 16-39 years of age.
  • not having suffered leg injuries in the past 6 months.
  • not having suffered a triceps sural rupture in the past two years.
  • be diagnosed with latent MTPs in the gastric-soleus complex through manual therapy in the dominant side.
  • Presence of Calf muscles Strain evaluated by Ultrasonography.
  • Athlete willing and able to participate in an exercise program safely.
  • The radiologist also assessed whether the tendon ends could be reduced in passive plantar flexion of the ankle joint with the knee extended.
  • Athlete BMI from 18.5 to 24.9 kg / m2

You may not qualify if:

  • connective tissue pathology.
  • lymphatic disorders (lymphadenopathy).
  • Skin injuries (open wounds, infection, psoriasis, tattoos, hematoma).
  • peripheral neuropathies.
  • previous fractures.
  • previous lower limb surgeries (in the past 12 months).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Sprains and Strains

Condition Hierarchy (Ancestors)

Wounds and Injuries

Central Study Contacts

Nabil Abdel-Aal, professor

CONTACT

01200133613nabil.mahmoud@cu.edu.eg

Hossam Mostafa, master

CONTACT

01092727746h.elshatory@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
opaque sealed envelope
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: TECAR and conventional therapy
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
principle investigator : nabil mahmoud ismail

Study Record Dates

First Submitted

April 25, 2026

First Posted

May 1, 2026

Study Start

May 1, 2026

Primary Completion (Estimated)

December 1, 2026

Study Completion (Estimated)

December 1, 2026

Last Updated

May 1, 2026

Record last verified: 2026-04